Table 1.
Metabolic profiles at baseline and after the 12-week intervention in patients with diabetic hemodialysis that received either CoQ10 supplements or placebo
| Placebo group (n=30) | Q10 group (n=30) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | End-of-trial | Mean±SD | P1 | Baseline | End-of-trial | Mean±SD | P1 | P2 | |
| TAC (mmol/L) | 846.079±144.443 | 743.923±149.011 | −126.781±26.437 | 0.002 | 650.470±87.829 | 680.765±108.302 | 54.921±26.437 | 0.26 | <0.001 |
| 883.430 (514.50-1182.03) | 716.430 (513.20-1156.54) | 644.650 (528.24-816.28) | 659.570 (528.24-893.88) | ||||||
| GSH (µmol/L) | 520.653±0.212 | 5.02±3.42 | 60.750±32.617 | 0.711 | 415.155±58.467 | 420.82±67.762 | -34.895±32.617 | 0.745 | 0.053 |
| 0.460 (0.27-9.93) | 3.96 (326.1118.03) | 391.590 (362.12-601.10) | 393.220 (358.85-597.82) | ||||||
| MDA (µmol/L) | 3.3277±1.195 | 4.048±2.817 | 0.547±0.265 | 0.084 | 15.39±6.34 | 2.900±0.260 | −0.129±0.265 | 0 | 0.09 |
| 2.825 (1.87-6.63) | 2.465 (0.64-10.23) | 14.05 (3.40-33) | 2.885 (2.30-3.44) | ||||||
| hs-CRP (mg/L) | 6.793±3.520 | 7.110±3.769 | 0.345±0.583 | 0.398 | 7.340±6.378 | 6.066±4.699 | −1.302±0.583 | 0.07 | 0.042 |
| 6.250 (0.90-14.40) | 6.150 (0.80-18.70) | 6.100 (1.00-30.50) | 34.050 (31.35-45.14) | ||||||
| NO (µmol/L) | 44.480±6.165 | 43.173±7.636 | −1.427±1.314 | 0.362 | 34.050 (31.35-45.14) | 38.085 (31.03-48.00) | 4.121±1.314 | 0.001 | 0.006 |
| 41.770 (36.00-61.82) | 41.140 (32.00-64.50) | ||||||||
1Data are means±SDs. 2Obtained from repeated measures ANOVA test, TAC=Total antioxidant capacity, GSH=Total glutathione, MDA=Malondialdehyde, hs-CRP=High-sensitivity C-reactive protein, NO=Nitric oxide, ANOVA=Analysis of variance